

SHL/SEC/2022

November 14, 2022

The Bombay Stock Exchange Limited  
Listing Department,  
1<sup>st</sup> Floor, New Trading Ring,  
Rotunda Building,  
Phiroze Jeejeebhoy Towers, Dalal Street, Fort  
Mumbai – 400 001.

The Calcutta Stock Exchange Ltd.  
7, Lyons Range  
Kolkata - 700 001 India

Company Code: 537253

Dear Sir,

Sub. : **Outcome of the 250<sup>th</sup> Board Meeting held on 14.11.2022.**

Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we are pleased to inform that, the Board of Directors of the Company at their Board Meeting held today on Monday, November 14, 2022, inter-alia has approved the following:

1. Approved Unaudited Financial Results (Standalone & consolidated) for the 2<sup>nd</sup> quarter/1<sup>st</sup> half year ended on September 30, 2022 of the financial year 2022-23 and noted Limited Review Report on the same (Copy enclosed as Annexure-1).
2. Appointment of Mr. Satyendu Pattnaik as Company Secretary (KMP) & Compliance officer of the Company w.e.f. 14.11.2022.

The said Board Meeting of the Company was started at 04:05p.m., and concluded at 06.25 p.m.

You are requested to take the above information in your record and oblige us.

Thanking you,  
Yours sincerely,  
for **Sunil Healthcare Limited**



Satyendu Pattnaik  
Company Secretary  
FCS-7736  
Date: 14.11.2022  
Place: New Delhi  
Encl.: a/a



**SUNIL HEALTHCARE LIMITED**

Registered Office

38E/252-A, Vijay Tower, Shahpurjat, New Delhi-110049  
Email: info@sunilhealthcare.com; website: www.sunilhealthcare.com  
CIN : L24302DL1973PLC189662

**STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2022**

Rs. in Lakhs

	Particulars	Standalone					Year Ended	Consolidated					Year Ended
		Quarter ended		Half Year Ended		31st March 2022	31st March 2022	Quarter ended		Half Year Ended		31st March 2022	31st March 2022
		30th September 2022	30th June 2022	30th September 2021	30th September 2022	30th September 2021		30th September 2022	30th June 2022	30th September 2021	30th September 2022	30th September 2021	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	3,178.02	3,408.11	2,806.43	6,586.13	5,424.42	11,637.29	3,064.06	3,340.59	2,918.67	6,404.65	5,569.45	11,916.41
2	Other Income	57.63	33.53	51.78	91.16	70.37	155.42	177.18	91.73	42.59	268.91	67.00	167.55
3	<b>Total Income (1+2)</b>	<b>3,235.65</b>	<b>3,441.64</b>	<b>2,858.21</b>	<b>6,677.29</b>	<b>5,494.79</b>	<b>11,792.71</b>	<b>3,241.24</b>	<b>3,432.32</b>	<b>2,961.26</b>	<b>6,673.56</b>	<b>5,636.45</b>	<b>12,083.96</b>
4	<b>Expenses</b>												
a)	Cost of Materials consumed	1,362.09	1,253.00	997.78	2,615.09	1,999.92	4,290.14	1,362.09	1,253.00	997.78	2,615.09	1,999.92	4,290.14
b)	Purchase of Stock-in-trade	1.36	0.23	-	1.59	-	39.99	1.36	0.23	-	1.59	-	39.99
c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(126.78)	(91.32)	246.45	(218.10)	400.05	360.72	(151.40)	(113.71)	332.65	(265.11)	494.22	515.15
d)	Employees benefit expenses	419.35	390.16	337.79	809.51	687.52	1,418.97	419.35	390.16	337.79	809.51	687.52	1,418.97
e)	Finance Costs	110.04	81.88	91.06	191.92	197.52	348.88	110.04	81.88	91.06	191.92	197.52	348.88
f)	Depreciation and amortisation	170.89	163.03	157.59	333.92	312.93	630.57	170.93	163.07	157.63	334.00	313.01	630.73
g)	Other Expenses	983.54	1,034.66	969.10	2,018.20	1,801.32	3,746.33	1,025.33	1,075.26	1,020.26	2,100.59	1,888.36	3,913.63
	<b>Total Expenses</b>	<b>2,920.49</b>	<b>2,831.64</b>	<b>2,799.77</b>	<b>5,752.13</b>	<b>5,399.26</b>	<b>10,835.60</b>	<b>2,937.70</b>	<b>2,849.89</b>	<b>2,937.17</b>	<b>5,787.59</b>	<b>5,580.55</b>	<b>11,157.49</b>
5	<b>Profit before tax (3-4)</b>	<b>315.16</b>	<b>610.00</b>	<b>58.44</b>	<b>925.16</b>	<b>95.53</b>	<b>957.11</b>	<b>303.54</b>	<b>582.43</b>	<b>24.09</b>	<b>885.97</b>	<b>55.90</b>	<b>926.47</b>
6	<b>Tax Expenses (Net)</b>	<b>90.26</b>	<b>163.25</b>	<b>18.79</b>	<b>253.51</b>	<b>28.38</b>	<b>279.43</b>	<b>90.89</b>	<b>163.93</b>	<b>20.12</b>	<b>254.82</b>	<b>31.09</b>	<b>284.41</b>
a)	Current Tax												
i)	Current Tax	63.88	101.82	(16.76)	165.70	16.59	152.39	64.51	102.50	(16.06)	167.01	17.94	156.00
ii)	Tax for Earlier Period	-	-	-	-	-	(0.91)	-	-	0.63	-	1.36	0.46
b)	Deferred Tax Charged/(Credit)	26.38	61.43	35.55	87.81	11.79	127.95	26.38	61.43	35.55	87.81	11.79	127.95
7	<b>Profit/(loss) after tax (5-6)</b>	<b>224.90</b>	<b>446.75</b>	<b>39.65</b>	<b>671.65</b>	<b>67.15</b>	<b>677.68</b>	<b>212.65</b>	<b>418.50</b>	<b>3.97</b>	<b>631.15</b>	<b>24.81</b>	<b>642.06</b>
8	<b>Other Comprehensive Income (OCI)</b>												
a)	Items that will not be reclassified to Profit or Loss (net of tax)	-	-	-	-	-	(5.97)	(8.62)	(11.12)	2.00	(19.74)	(4.24)	(5.97)
b)	Items that will be reclassified to Profit or Loss (net of tax)	-	-	-	-	-	-	(8.62)	(11.12)	2.00	(19.74)	(4.24)	(12.33)
9	<b>Total Comprehensive Income (7+8)</b>	<b>224.90</b>	<b>446.75</b>	<b>39.65</b>	<b>671.65</b>	<b>67.15</b>	<b>671.71</b>	<b>204.03</b>	<b>407.38</b>	<b>5.97</b>	<b>611.41</b>	<b>20.57</b>	<b>642.06</b>
10	Paid-up equity share capital (Face value per share Rs.10/-)	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48
11	Other Equity						4,453.49						3,970.01
12	Earning per share of Rs.10/- each(not annualised except for year end)												
(a)	Basic (Rs.)	2.19	4.36	0.39	6.55	0.65	6.61	2.07	4.08	0.04	6.15	0.24	6.26
(b)	Diluted (Rs.)	2.19	4.36	0.39	6.55	0.65	6.61	2.07	4.08	0.04	6.15	0.24	6.26

*Signature*  
38E/252-A  
Vijay Tower  
Shahpurjat  
New Delhi  
110049



## Statement of Assets and Liabilities

2	Particulars	Standalone		Consolidated	
		As at	As at	As at	As at
		30th Sep.	31st Mar.	30th Sep.	31st Mar.
		2022	2022	2022	2022
		Un-audited	Audited	Un-audited	Audited
A	<b>ASSETS</b>				
1	<b>Non Current Assets</b>				
(a)	<b>Fixed Assets</b>				
	(i) Property, Plant and Equipment	5,648.17	5,520.87	5,648.49	5,521.26
	(ii) Capital Work-in-Progress	132.20	175.06	132.20	175.06
	(iii) Right of Use Assets	1,446.77	1,458.84	1,446.77	1,458.84
	(iv) Other Intangible Assets	14.49	16.79	14.49	16.79
(b)	<b>Financial Assets</b>				
	(i) Investment	13.01	116.28	-	103.27
	(ii) Other Financial Assets	199.37	99.28	199.37	99.28
(c)	<b>Other non-current Assets</b>	25.33	113.96	25.33	113.96
2	<b>Current Assets</b>				
(a)	<b>Inventories</b>	871.76	993.43	1,049.16	1,105.49
(b)	<b>Financial Assets</b>				
	(i) Loan	32.62	30.32	-	-
	(ii) Trade Receivables	3,147.22	2,199.86	2,477.37	1,889.18
	(iii) Cash and Cash Equivalents	1.34	3.42	73.91	26.60
	(iv) Other Bank Balances	334.93	319.26	334.93	319.26
	(v) Other Financial Assets	51.74	59.48	13.00	23.49
(c)	<b>Current Tax Assets</b>	-	7.10	-	3.84
(d)	<b>Other Current Assets</b>	124.36	104.37	144.65	112.81
	<b>TOTAL ASSETS</b>	<b>12,043.31</b>	<b>11,218.32</b>	<b>11,559.67</b>	<b>10,969.13</b>
B	<b>EQUITY AND LIABILITIES</b>				
1	<b>Equity</b>				
	(a) Equity Share Capital	1,025.48	1,025.48	1,025.48	1,025.48
	(b) Other Equity	5,125.14	4,453.49	4,581.42	3,970.01
2	<b>Non Current Liabilities</b>				
	(a) Financial Liabilities				
	(i) Borrowings	1,138.90	1,082.74	1,138.90	1,082.74
	(ii) Lease Liability	15.82	21.75	15.82	21.75
	(b) Provisions	239.05	207.31	239.05	207.31
	(c) Deferred Tax Liabilities (Net)	768.50	680.69	768.50	680.69
3	<b>Current Liabilities</b>				
	(a) Financial Liabilities				
	(i) Borrowings	2,070.40	2,339.52	2,070.40	2,339.52
	(ii) Trade Payables				
	Total Outstanding dues of Micro enterprises and small enterprises	197.79	213.61	197.79	213.61
	Total Outstanding dues of Creditors other than Micro enterprises and small enterprises	963.20	614.57	998.68	649.74
	(iii) Lease Liabilities	18.36	24.41	18.36	24.41
	(iv) Other Financial Liabilities	66.81	68.44	66.81	68.44
	(b) Other Current Liabilities	226.44	352.85	246.22	551.97
	(c) Provisions	108.71	108.71	108.71	108.71
	(d) Current tax liabilities(Net)	78.71	24.75	83.53	24.75
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>12,043.31</b>	<b>11,218.32</b>	<b>11,559.67</b>	<b>10,969.13</b>

Chartered Accountant
   
 No. 252/A
   
 New Delhi
   
 110019

Rs. in Lakhs

Cash Flow Statement		Standalone		Consolidated	
3	Particulars	For the Half	For the Half	For the Half	For the Half
		year ended	year ended	year ended	year ended
		30th Sep 2022	30th Sep 2021	30th Sep 2022	30th Sep 2021
		Un-audited	Un-audited	Un-audited	Un-audited
<b>A. Cash Flow From Operating Activities</b>					
	Profit before Tax from continued business	925.16	95.53	885.97	55.90
	Adjustment for :				
	Finance Costs	191.92	197.52	191.92	197.52
	Depreciation and Amortization Expenses	333.92	312.93	334.00	313.01
	Sundry balances written back	2.48	69.57	2.48	69.57
	(Profit)/Loss on Sales/Discarded of Property ,Plant and Equipment	(2.24)	0.47	(2.24)	0.47
	Interest Income	(8.25)	(11.67)	(8.25)	(11.49)
	Fair valuation of Investments measured at FVTPL	-	(1.71)	-	(1.71)
	Profit on sale of Investments measured at FVTPL	(0.49)	0.01	(0.49)	0.01
	Baddebts/Provision for loss allowances	54.82	306.27	54.82	306.27
	Liabilities/ Provisions no longer required written back	(8.27)	-	(210.34)	(0.01)
	Unrealised (gain)/loss foreign currency transactions and translation/FCTR	(85.41)	(9.37)	(42.41)	(13.32)
	<b>Operating profit before working capital changes</b>	<b>1,403.64</b>	<b>959.55</b>	<b>1,205.46</b>	<b>916.22</b>
	Changes in working Capital:				
	(Increase)/Decrease in Inventories	121.67	330.52	56.33	415.07
	(Increase)/Decrease in Trade and other Receivables	(948.79)	69.29	(659.23)	51.81
	Increase /(Decrease) in Trade and other payable	246.40	(233.44)	269.45	(209.08)
	<b>Cash generation from Operation</b>	<b>822.92</b>	<b>1,125.92</b>	<b>872.01</b>	<b>1,174.02</b>
	Payment of Direct Taxes	(104.63)	(0.97)	(104.39)	(2.65)
	<b>Net Cash generated/ (used) - Operating Activities</b>	<b>718.29</b>	<b>1,124.95</b>	<b>767.62</b>	<b>1,171.37</b>
<b>B. Cash Flow from Investing Activities</b>					
	Purchase of Property, Plant and Equipment & Intangible Assets	(341.58)	(405.20)	(341.58)	(405.20)
	Sale of Property, Plant and Equipment	23.70	0.31	23.70	0.31
	Sale of Mutual Funds	103.76	5.96	103.76	5.96
	Movement in Receivable from subsidiaries	-	82.34	-	-
	Movement in Term Deposits	(115.67)	373.14	(115.67)	373.14
	Interest Received	19.59	6.61	19.65	6.61
	<b>Net Cash Generated/ (Used) - Investing Activities</b>	<b>(310.20)</b>	<b>63.16</b>	<b>(310.14)</b>	<b>(19.18)</b>
<b>C. Cash Flow from Financing Activities</b>					
	Receipts from Non Current Borrowings	370.50	-	370.50	-
	Repayment of Non Current Borrowings	(281.32)	(251.98)	(281.32)	(251.98)
	Loan repaid to Director	(91.00)	(237.00)	(91.00)	(237.00)
	Receipts/(Repayment) of Short-term Borrowings (Net)	(228.41)	(506.44)	(228.41)	(506.44)
	Payment of lease liability	(11.98)	(11.12)	(11.98)	(11.12)
	Finance Cost Paid	(167.96)	(179.86)	(167.96)	(179.86)
	<b>Net Cash Generated/ (Used) - Financing Activities</b>	<b>(410.17)</b>	<b>(1,186.40)</b>	<b>(410.17)</b>	<b>(1,186.40)</b>
	<b>Net Increase/ (Decrease) in Cash and Cash Equivalents (A+B+C)</b>	<b>(2.08)</b>	<b>1.71</b>	<b>47.31</b>	<b>(34.21)</b>
	Add : Opening Cash and Cash Equivalents	3.42	4.81	26.60	55.20
	<b>Closing Cash and Cash Equivalents</b>	<b>1.34</b>	<b>6.52</b>	<b>73.91</b>	<b>20.99</b>

4 As the Company's business fall within a single primary business segment viz. sale of capsule, the disclosure requirement of Indian Accounting Standard (Ind AS-108) "Operating Segments" prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder, is not applicable.

5 The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on November 14, 2022.

6 The figures for the previous periods have been regrouped/ rearranged, wherever considered necessary, to conform current period classifications.

Place: NEW DELHI  
Date: 14/11/2022



Anil Khaitan  
(Chairman cum Managing Director)  
DIN 00759951



**Review Report on unaudited standalone quarterly and half yearly financial results Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended**

**To the Board of Directors of Sunil Healthcare Limited**

We have reviewed the accompanying statement of unaudited standalone financial results ("Statement") of Sunil Healthcare Limited ("the Company") for the quarter and half year ended September 30, 2022. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

The review/ audit of standalone financial results for the quarter ended June 30, 2022, for the quarter and half year ended September 30, 2021 and for the year ended March 31, 2022 included in statement are carried out by previous auditor, whose report issued on July 20, 2022, October 27, 2021 and May 06, 2022 respectively expressed Unmodified opinion on those financial results/ financial statements.

Place: Noida (Delhi-NCR)  
Date: November 14, 2022



For Singhi & Co.  
Chartered Accountants  
Firm Registration No. 302049E

  
Bimal Kumar Sipani  
Partner

Membership No. 088926  
UDIN: 22088926BDBRJK7835

**Independent Auditor's Review Report on consolidated unaudited quarterly and half yearly financial results of Sunil Healthcare Limited, Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended**

To Board of Directors of Sunil Healthcare Limited

1. We have reviewed the accompanying statement of consolidated unaudited financial results of Sunil Healthcare Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and half year ended September 30, 2022, ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities
  - a. Sunil Healthcare Mexico SA De CV (Incorporated in Mexico)
  - b. Sunil Healthcare North America LLC (Incorporated in USA)





5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement read with notes therein, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The consolidated unaudited financial results include the interim financial results of two foreign subsidiaries whose financial statements are not required to review according to the law of respective countries and whose financial results reflect total assets of Rs. 720.60 Lakhs as at September 30, 2022 and total revenue from operation of Rs. 27.13 Lakhs and Rs. 96.84 Lakhs, Loss after tax of Rs. 0.03 Lakhs and Rs. 0.02 Lakhs and total comprehensive income of Rs. (8.62) Lakhs and Rs. (19.74) Lakhs for the quarter and half year ended September 30, 2022 respectively and net cash inflow of Rs. 49.39 Lakhs for the half year ended September 30, 2022 as considered in the Statement. According to the information and explanations given to us by the management, these Interim financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

The review/ audit of consolidated financial results for the quarter ended June 30, 2022, for the quarter and half year ended September 30, 2021 and for the year ended March 31, 2022 included in statement are carried out by previous auditor, whose report issued on July 20, 2022, October 27, 2021 and May 06, 2022 respectively expressed unmodified opinion on those financial results/ financial statements.

Place: Noida (Delhi-NCR)  
Date: November 14, 2022



For Singhi & Co.  
Chartered Accountants  
Firm Registration No. 302049E

  
Bimal Kumar Sipani  
Partner

Membership No. 088926  
UDIN: 22088926BDBRTT3317